Hidden Gene's Toll: Dr. Egbuna Uncovers Kidney Disease Crisis

A silent killer has long plagued the Black community, driving kidney failure rates to alarming highs. Now, dedicated medical research is shining a crucial light on a genetic culprit, with Dr. Ogo Egbuna at the forefront of this groundbreaking investigation.

Black Americans experience kidney failure at rates four to five times higher than their European American counterparts. Despite making up approximately 14% of the U.S. population, this community accounts for a staggering 30% of all kidney failure cases. For decades, this stark disparity was broadly attributed to conditions like high blood pressure and diabetes, a generalization that, as Dr. Egbuna points out, "did not consider the specific genetic drivers of some forms of kidney disease that can affect people of African ancestry."

The focus of Dr. Egbuna's extensive work is APOL1-mediated kidney disease, or AMKD. This aggressive form of kidney disease is fueled by particular variants of the APOL1 gene, known as G1 and G2. These genetic variants are found almost exclusively in individuals of West African descent, tracing their origins back thousands of years when they evolved to provide protection against the *Trypanosoma brucei rhodesiense* parasite, the cause of African sleeping sickness.

However, this ancient protective mechanism comes with a severe modern-day cost. Individuals who inherit two copies of these specific genetic variants face a significantly elevated risk of developing severe kidney disease and progressing rapidly to kidney failure. While every person possesses the APOL1 gene, certain genetic changes are more common in people of African ancestry. Estimates indicate that about 13% of Black Americans carry two high-risk APOL1 genetic variations, and among this group, there is approximately a one in five chance of developing kidney disease.

Dr. Ogo Egbuna brings nearly two decades of expertise to the intersection of clinical medicine and drug development, all dedicated to kidney disease. His impressive academic and professional journey includes training at prestigious institutions such as Mount Sinai, the University of Rochester, Beth Israel Deaconess Medical Center, Harvard, and MIT. An internist-transplant nephrologist, Dr. Egbuna completed medical school at the University of Nigeria before his specialized training in the United States. He spent a decade at Amgen before joining Vertex Pharmaceuticals, where he currently serves as Vice President of Clinical Development and Global Clinical Development Lead for the company's APOL1-mediated kidney disease program. He also contributes his expertise to the board of the Kidney Health Initiative, a collaborative effort between the FDA and the American Society of Nephrology.

The critical role of APOL1 variants in explaining this health disparity became clear with their discovery in 2010. Further solidifying this understanding, a study published in *Nature Medicine* on March 20, 2017, definitively proved that certain variants of the APOL1 gene cause kidney disease. Professor Jeff Miner, a co-author of the study, expressed his satisfaction, stating, "I am thrilled to have been able to participate in a study that helps us to better understand the pathogenesis of kidney disease in African-Americans."

Dr. Egbuna has been a tireless advocate for increasing public awareness and promoting early screening, including genetic testing, to accurately identify the underlying cause of kidney disease. He emphasizes that "kidney disease often progresses silently, is underdiagnosed, and is sometimes mislabeled as something else. Too many individuals receive a diagnosis only when their condition has reached an advanced stage, and even then, the diagnosis might not tell the full story or could be wrong entirely." He has shared his insights at various public forums, including an NMQF Webinar on March 18, 2022, and the Black Health Matters Summit on June 8, 2022. Regarding the challenging yet promising path of developing new therapies, he remarked in a March 20, 2024, podcast, "Nothing good or great comes easy. Therein lies the promise and the excitement."

His team at Vertex Pharmaceuticals is actively engaged in developing potential small molecule therapies specifically designed to target the root cause of AMKD. A significant stride in this effort was the publication of results from a single-group phase 2a clinical study on Inaxaplin in the *New England Journal of Medicine* on March 16, 2023. This investigational therapy, co-authored by Dr. Egbuna, aims to inhibit APOL1 function. The study, involving 13 participants with two APOL1 variants and biopsy-proven focal segmental glomerulosclerosis, demonstrated a significant reduction in protein excretion. Dr. Egbuna's team concluded that "these data provide a rationale to test the hypothesis that with a longer treatment period, Inaxaplin therapy may prevent or slow progression to end-stage kidney disease." He has openly shared his enthusiasm for this work, stating, "This is actually one of the most difficult kidney diseases that have plagued a minority population and underserved population for so long... But we do know now that there is a genetic basis for a lot of this disparity."

The narrative of APOL1-mediated kidney disease is also deeply connected to broader discussions about racial bias in medical diagnostics. For many years, a race-based modifier was incorporated into the estimated glomerular filtration rate (eGFR) equation, a standard clinical laboratory test used to assess kidney function. This context highlights the long-standing need for more precise, genetically informed diagnostic and treatment approaches that move beyond broad racial categorizations.

The ongoing research and advocacy led by Dr. Egbuna represent a critical turning point in addressing a major health disparity affecting the Black community. With the promise of targeted therapies like Inaxaplin, the medical community is hopeful that understanding the genetic basis of AMKD will lead to earlier diagnoses, more effective treatments, and ultimately, a significant reduction in kidney failure rates for those most vulnerable. The continued development of these therapies will be a key area to watch.